Zometa

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

By |2017-10-19T10:54:43-04:00August 9th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Metastases, On The Horizon, Uncategorized, Understanding APC|0 Comments
Read More

A Priority FDA Review for Toremifene 80 mg for Bone Protection

GTx announced in a company media release that it has requested that the FDA consider its new drug application (NDA) for the use of toremifene 80 mg to prevent bone fractures in men with prostate cancer receiving androgen deprivation therapy (ADT). GTx has asked for a priority review of its application stating that “there are [...]

By |2009-01-01T11:37:15-05:00January 1st, 2009|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, FDA, Financial, Hormone Therapy, How We Live, Metastases, Politics of Cancer, Uncategorized|0 Comments
Read More
Go to Top